ANDA 76694, held by Pharmobedient. Quinapril Hydrochloride.
As of Nov 16, 2026, ANDA 76694 (Quinapril Hydrochloride), held by Pharmobedient, was first approved by FDA on Dec 23, 2004, with 5 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 23, 2004 | Original application | Approved | None posted |
| Quinapril HydrochlorideEQ 5MG BASE · tablet;oral | Quinapril Hydrochloride | Discontinued |
| Quinapril HydrochlorideEQ 10MG BASE · tablet;oral | Quinapril Hydrochloride | Discontinued |
| Quinapril HydrochlorideEQ 20MG BASE · tablet;oral | Quinapril Hydrochloride | Discontinued |
| Quinapril HydrochlorideEQ 40MG BASE · tablet;oral | Quinapril Hydrochloride | Discontinued |
| Sep 28, 2026 | Supplement 17Labeling · Standard review | Approved | None posted |
| Oct 23, 2025 | Supplement 13Labeling · Standard review | Approved | None posted |
| Oct 23, 2025 | Supplement 14Labeling · Standard review | Approved | None posted |
| Feb 17, 2011 | Supplement 10Labeling | Approved | None posted |
| Apr 28, 2006 | Supplement 5Labeling | Approved | None posted |
| Dec 23, 2004 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters